David Goggins
Former Navy Seal
Career Development
Bryan Cranston
Critical Thinking
Liv Boeree
International Poker Champion
Emotional Intelligence
Amaryllis Fox
Former CIA Clandestine Operative
Chris Hadfield
Retired Canadian Astronaut & Author
from the world's big
Start Learning

Human CRISPR Trials Will Happen in 2018. They'll Look Like This.

Genetic editing in people gathers steam.

“Every new and hot biomedical technology usually undergoes an inflated expectations phase,” Alexey Bersenev, director of the Advanced Cell Therapy Lab at Yale-New Haven Hospital tells MIT Technology Review. When CRISPR-Cas9 was first introduced in 2014, the sky seemed to be the limit when it came to all the genetic issues it could conceivably repair. As with any potentially life-saving medical breakthrough, the hopes of many leaped, quite naturally, to a future in which CRISPR-Cas9 was readily available and in wide use. CRISPR-Cas9 still retains that tremendous promise, but the reality is that that these things take time. China has a number of human CRISPR trials underway, though no results have yet been made available. And now, finally, human trials are about to get underway in Europe and the U.S.

The targets of the U.S. and European trials are two genetic blood disorders that ruin hemoglobin: sickle-cell anemia and beta thalassemia. Sickle-cell disease is among the most common genetic maladies, with millions affected worldwide. When someone has sickle-cell, painful blood-vessel blockages can occur, as can anemia, infections, and eye problems. Sickle-Cell sufferers are also at increased risk of strokes, and heart, kidney, and liver damage.

The sickle cell, shaped like a farmer’s sickle, is to the left of four normal blood cells. (OPEN STAX COLLEGE)

Major beta thalassemia, also called “Cooley’s anemia,” develops shortly after birth and is a progressive condition that prevents an infant from developing normally, best by feeding problems, fever, and intestinal distress, including diarrhea. 

The Europe and U.S. treatments involve two companies. CRISPR Therapeutics, founded by Emmanuelle Charpentier, one of the co-inventors of CRISPR-Cas9, has asked regulators in Europe for permission to treat beta thalassemia, hopefully during 2018. They also plan to request approval within the next six months from the U.S. Food and Drug Administration (FDA) for sickle-cell treatments. Researchers at Stanford University School of Medicine are also planning to begin sickle-cell CRISPR therapy at their Center for Curative and Definitive Medicine, and intend to seek permission from the FDA in 2018.

There’s reason to take baby steps with such a powerful technology — just ask Jennifer Doudna, CRISPR-Cas9’s other co-inventor — with technical and ethical issues to be addressed prior to editing genes for reinfusion into living patients.

There have been other attempts at beginning clinical trials that have stalled. The University of Pennsylvania last year received permission from the National Institutes of Health (NIH) and the FDA to begin CRISPR treatments for melanoma, sarcoma, and multiple myeloma in 2017. They have yet to get underway; it’s not clear why. Editas Medicine’s planned clinical trials of a treatment for inherited blindness hit a manufacturing bottleneck and has been postponed. Intellia Therapeutics hasn’t announced any trials yet.

CRISPR Therapeutics and Stanford are approaching the problematic hemoglobin in sickle cell and beta thalassemia in different ways, though both will be taking stem cells from patients’ bone marrow.


CRISPR Therapeutics plans to “make a single genetic change that is designed to increase fetal hemoglobin levels in a patient’s own blood cells. The edited cells are then reinfused and are expected to produce red blood cells that contain fetal hemoglobin in the patient’s body, thereby overcoming the hemoglobin deficiencies caused by the disease.” Stanford plans to repair the defective hemoglobin using CRISPR before returning it to patients’ bodies — since sickle cells live only about 10-20 days, and healthy cells from 90 to 120 days, it’s their expectation that healthy cells will soon be in the majority. This matters because patients whose sickle cell counts are below 30% have no symptoms.

It may not yet the gene-editing world we may have imagined when we first learned of CRISPR-Cas9, but it looks like 2018 may be the year that future finally gets underway at last.


The “new normal” paradox: What COVID-19 has revealed about higher education

Higher education faces challenges that are unlike any other industry. What path will ASU, and universities like ASU, take in a post-COVID world?

Photo: Luis Robayo/AFP via Getty Images
Sponsored by Charles Koch Foundation
  • Everywhere you turn, the idea that coronavirus has brought on a "new normal" is present and true. But for higher education, COVID-19 exposes a long list of pernicious old problems more than it presents new problems.
  • It was widely known, yet ignored, that digital instruction must be embraced. When combined with traditional, in-person teaching, it can enhance student learning outcomes at scale.
  • COVID-19 has forced institutions to understand that far too many higher education outcomes are determined by a student's family income, and in the context of COVID-19 this means that lower-income students, first-generation students and students of color will be disproportionately afflicted.
Keep reading Show less

4 ways to promote neurogenesis in your brain

How can we promote the creation of new neurons - and why is it so important?

We can promote the development of new neurons well into adulthood - and here's why we should.

Image by vrx on Shutterstock
Mind & Brain
  • Neurogenesis, the birth of neurons from stem cells, happens mostly before we are born - as we are formed in the womb, we are generating most of what we need after birth.
  • After birth, neurogenesis is still possible in two parts of the brain: the olfactory bulb (which is responsible for our sense of smell) and the hippocampus (which is responsible for memory, spatial navigation, and emotional processing).
  • Research from the 1960s proves creating new neurons as adults is possible, and modern-day research explains how (and why) we should promote new neuron growth.
Keep reading Show less

Live on Tuesday | Personal finance in the COVID-19 era

Sallie Krawcheck and Bob Kulhan will be talking money, jobs, and how the pandemic will disproportionally affect women's finances.

How DNA revealed the woolly mammoth's fate – and what it teaches us today

Scientists uncovered the secrets of what drove some of the world's last remaining woolly mammoths to extinction.

Ethan Miller/Getty Images
Surprising Science

Every summer, children on the Alaskan island of St Paul cool down in Lake Hill, a crater lake in an extinct volcano – unaware of the mysteries that lie beneath.

Keep reading Show less
Scroll down to load more…